Obsessive-Compulsive Symptoms in Schizophrenia: Are They Manifestations of a Distinct Subclass of Schizophrenia?

CNS Spectrums

Volumn 2, Issue 3, 1997, Pages 45-48

  Berman, Ileana ^a   Pappas, Demetra ^a   Berman, Stuart M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85011486602     PISSN: 10928529     EISSN: 21656509     Source Type: Journal    
DOI: 10.1017/S1092852900004600     Document Type: Article

References (43)

1. Stengel, E. A study of some clinical aspects of the relationship between obsessional neurosis and psychotic reaction types. J Ment Sci. 1945; 91: 166–187.
2. Rosen, I. The clinical significance of obsessions in schizophrenia. J Ment Sci. 1957; 103: 773–785.
3. Fenton, WS, McGlashan, TH. The prognostic significance of obsessive-compulsive symptoms in schizophrenia. Am J Psychiatry. 1986; 143: 437–441.
4. Sullivan, HS. Clinical Studies in Psychiatry. New York, NY: WW Norton Company; 1956.
5. Parkin, A. Neurosis and schizophrenia: II. modern perspectives. Psychiatry Q. 1966; 40: 217–235.
6. Birnie, WA, Litman, SK. Obsessionality in schizophrenia. Can Psychiatr Assoc J. 1978; 23: 77–81.
7. Berman, I, Kalinowski, A, Berman, SM, Lengua, J, Green, AI. Obsessive and compulsive symptoms in chronic schizophrenia. Comp Psychiatry. 1995; 36: 6–10.
8. Samuel, J, Nesdadt, G, Walyniec, P, Adler, L, Liong, KY, Pulver, AE. Obsessive-compulsive symptoms in schizophrenia. Schizophr Res. 1993; 9: 139.
9. Bermanzohn, P, Siris, S. Comorbidity in schizophrenia. Presented at the APA Annual Meeting; 1995; Miami, Fla.
10. Insel, TR, Akiskal, HS. Obsessive-compulsive disorder with psychotic features: a phenomenologic analysis. Am J Psychiatry. 1986; 143: 1527–1533.
11. Berman, I, Merson, A, Viegner, B, Losonczy, MF, Pappas, D, Green, AI. Obsessions and compulsions as a distinct cluster of symptoms in schizophrenia: a neuropsychological study. In press.
12. Murphy, DL, Zohar, J, Bekelfat, C, et al. Obsessive-compulsive disorder as a 5-HT subsystem-related behavioral disorder. Br J Psychiatry. 1989;(suppl):5–24.
13. Rapoport, JL. The biology of obsessions and compulsions. Sci Am. 1989; 260: 83–89.
14. Bekelfat, C, Murphy, DL, Zohar, J, Hill, JL, Grover, G, Insel, TR. Clomipramine in obsessive-compulsive disorder: further evidence for a serotonergic mechanism of action. Arch Gen Psychiatry. 1989; 45: 177–185.
15. Hollander, E, Fay, M, Cohen, B, Campeas, R, Gorman, JM, Liebowitz, MR. Serotonergic and noradrenergic sensitivity in obsessive-compulsive disorder: behavioral findings. Am J Psychiatry. 1988; 145: 1015–1017.
16. Davila, R. Plasma HVA, neuroleptics, dopaminergic plasticity. Biol Psychiatry. 1989; 25: 1–3.
17. Davidson, M, Kahn, RS. Knott, P, et al. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations. Arch Gen Psychiatry. 1991; 48: 910–913.
18. Thoren, P, Asberg, M, Bertilsson, L, Mellstrom, B, Sjoqvist, F, Traskman, L. Clomipramine treatment in obsessive-compulsive disorder. Arch Gen Psychiatry. 1980; 37: 1289–1294.
19. Berman, I, Viegner, B, Merson, A, Allan, E, Pappas, D, Green, AI. Differential relationships between positive and negative symptoms and neuropsychological deficits in schizophrenia. In press.
20. Addington, J, Addington, D, Matika-Tyndale, E. Cognitive functioning and positive and negative symptoms in schizophrenia. Schizophrenia Res. 1991; 5: 123–134.
21. Keefe, RSE. The contribution of neuropsychology to psychiatry. Am J Psychiatry. 1995; 152: 6–15.
22. Strauss, M. Relations of symptoms to cognitive deficits in schizophrenia. Schizophrenia Bull. 1993; 19: 215–231.
23. Head, D, Bolton, D, Hymas, N. Deficit in cognitive shifting ability in patients with obsessive-compulsive disorders. Biol Psychiatry. 1989; 25: 929–937.
24. Aronowitz, B, Hollander, E, DeCaria, C, et al. Neuropsychology of obsessive-compulsive disorder: preliminary findings. Neuropsychiatry, Neuropsychology and Behavioral Neurology. 1994; 7: 81–86.
25. Christensen, KJ, Kim, SW, Dysken, MW, Hoover, KM. Neuropsychological performance in obsessive-compulsive disorder. Biol Psychiatry. 1992; 31: 4–18.
26. Pato, MT, Zohar-Kadouch, R, Zohar, J, Murphy, DL. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am J Psychiatry. 1988; 145: 1521–1525.
27. Zohar, J, Kaplan, Z, Benjamin, J. Clomipramine treatment of obsessive compulsive symptomatology in schizophrenic patients. J Clin Psychiatry. 1993; 54: 385–388.
28. Berman, I, Sapers, BL, Chang, HHJ, Losonczy, MF, Schmilder, J, Green, AI. Treatment of obsessive-compulsive symptoms in schizophrenic patients with clomipramine. J Clin Psychopharmacol. 1995; 15: 206–210.
29. Barr, LC, Goodman, WK, Price, LH, McDougle, CJ, Charney, DS. The serotonin hypothesis of obsessive compulsive disorder: implication of pharmacologic challenge studies. J Clin Psychiatry. 1992; 53(suppl): 17–28.
30. Insel, TR, Mueller, EA, Alterman, I, Linnoila, M, Murphy, DL. Obsessive-compulsive disorder and serotonin: is there a connection? Biol Psychiatry. 1985; 20: 1174–1188.
31. Hollander, E, DeCaria, CM, Nitescu, A, et al. Serotonergic function in obsessive-compulsive disorder: behavioral neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry. 1992; 49: 21–28.
32. Bleich, A, Brown, SL, Kahn, R, van Praag, HM. The role of serotonin in schizophrenia. Schizophrenia Bull. 1988; 14: 297–315.
33. Iqbal, N, Asnis, GM, Wetzler, S, Kahn, RS, Kay, SR, van Praag, HM. The MCPP challenge test in schizophrenia: hormonal and behavioral responses. Biol Psychiatry. 1991; 30: 770–778.
34. Kahn, RS, Siever, LJ, Gabriel, S, et al. Serotonin function in schizophrenia: effects of meta-chlorophenylpiperazine in schizophrenic patients and healthy subjects. Psychiatiy Res. 1992; 43: 1–12.
35. Baker, RW, Chengappa, KNR, Baird, JW, Steingard, S, Christ, MAG, Schooler, NR. Emergence of obsessive compulsive symptoms during treatment with clozapine. J Clin Psychiatry. 1992; 53: 439–442.
36. LaPorta, LD. More on obsessive-compulsive symptoms and clozapine. J Clin Psychiatry. 1994; 55: 312. Letter.
37. Patil, VJ. Development of transient obsessive-compulsive symptoms during treatment with clozapine. Am J Psychiatry. 1992; 149: 272. Letter.
38. Cohen, LJ, Hollander, E, DeCaria, CM, et al. Specificity of neuropsychological impairment in obsessive-compulsive disorder: a comparison with social phobic and normal control subjects. J Neuropsychiatry Clin Neurosci. 1996; 8: 82–85.
39. Goldberg, TE, Gold, J. Neurocognitive functioning in patients with schizophrenia. In: Bloom, F, Kupfer, D, eds. Psycho-pharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995; 1245–1257.
40. Myers, JK, Weissman, MM, Tischler, GL, et al. Six-month prevalence of psychiatric disorders in three communities. Arch Gen Psychiatry. 1984; 41: 959–967.
41. McDougle, C, Goodman, WK, Leckman, JF, Price, LH. The psychopharmacology of obsessive compulsive disorder. Psychiatric Clin North Am. 1993; 16: 749–766.
42. Breese, GR, Baumeister, AA, McCown, TJ, et al. Behavioral differences between neonatal and adult 6-hydroxy-dopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine. J Pharmacol Exp Ther. 1984; 231: 343–354.
43. Jackson, D, Bruno, JP, Stachowiak, MK, et al. Inhibition of striatal acetylcholine release by serotonin and dopamine after the intracerebral administration of 6-hydroxy-dopamine to neonatal rats. Brain Res. 1988; 457: 267–273.